KRAS and cancer: We failed to observe any association between reoccurring mutations (TP53, PIK3CA, CDH1 and AKT1 in breast-derive cancer cell lines; TP53, MLH1, APC, KRAS, BRAF and PIK3CA in colorectal cancer cell lines; CTNNB1, TP53, AXIN1, JAK1 and LRP1B in hepatocarcinoma cell lines; TP53, PIK3CA and AKT1 in lung cancer cell lines) or microsatellite instability (MSI) and imprinted DMR status for any cell lines.